[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"large-core-infarct\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:large-core-infarct":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100619521","basilar-artery-occlusion-chinese-endovascular-registry-in-patients-with-large-core-infarct-100619521",false,"NCT07345702","Basilar Artery Occlusion Chinese Endovascular Registry in Patients With Large-Core Infarct","Endovascular Versus Medical Therapy for Acute Large-Core Basilar Artery Occlusion: A Multicenter Retrospective Registry Study (BAOCHE-LC)","BAOCHE-LC","Inclusion Criteria:\n\n1. Age ≥18 years, men or women.\n2. Occlusion (TIMI 0-1) of the basilar artery or intracranial segments of both vertebral arteries (V4) as evidenced by CTA\u002FMRA\u002FDSA.\n3. Time from symptom onset (or last known well) to treatment (endovascular therapy or medical therapy) ≤7 days.\n4. Patients with large core infarction in the posterior circulation, defined as a posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) score of 0-5 on CT angiography source images or MR with diffusion-weighted imaging or non-contrast CT.\n\nExclusion Criteria:\n\n1. Subjects with occlusions in both anterior and posterior circulation.\n2. CT or MR evidence of hemorrhage (the presence of microbleeds on MRI is allowed).\n3. Missing key clinical information (e.g., unavailable baseline NIHSS, unclear symptom onset\u002Flast known well time, or missing major treatment information including whether EVT was performed).\n4. Baseline NIHSS score \\\u003C6.\n5. Woman of childbearing potential who is known to be pregnant or lactating or who has a positive pregnancy test on admission.\n6. Missing follow-up outcomes at 90 days.\n7. Any other condition judged by investigators to substantially affect analysis or interpretation.","ALL","18 Years",{"count":20,"type":21},518,"ESTIMATED","OBSERVATIONAL","This multicenter retrospective registry study evaluates the safety and effectiveness of endovascular therapy versus medical therapy for acute large-core basilar artery occlusion. It also investigates clinical, imaging, and laboratory factors associated with functional outcomes and mortality. Patients are grouped according to the treatment received in routine clinical practice.",[25,26,27],"Basilar Artery Occlusion","Ischemic Stroke","Large Core Infarct","NOT_YET_RECRUITING","2026-01-15",{"date":31,"type":32},"2026-01-20","ACTUAL",{"date":34,"type":21},"2026-01-31",{"date":36,"type":21},"2026-10-31",{"name":38,"class":39},"Xuanwu Hospital, Beijing","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":40},"100599934","evt-in-acute-basilar-artery-occlusion-with-large-infarction-core-100599934","NCT07090941","EVT in Acute Basilar Artery Occlusion With Large Infarction Core","Trial of Endovascular Treatment in Acute Basilar Artery Occlusion Patients With a Large Infarct Core","BOLT","Inclusion Criteria:\n\n* 1\\. Age ≥18 years. 2. Symptoms and signs consistent with basilar artery ischemia. 3. Basilar artery or vertebral artery occlusion confirmed by computed tomography angiography (CTA), magnetic resonance angiography (MRA), digital subtraction angiography (DSA); if vertebral artery occlusion is present, it must completely obstruct blood flow to the basilar artery.\n\n  4\\. POST-NIHSS score ≥10 at randomization. 5. Time from symptom onset to randomization ≤24 hours (symptom onset defined as last known well time).\n\n  6\\. pc-ASPECTS of 3-5 on CT\u002FMRI (for patients aged \\\u003C80 years) or pc-ASPECTS of 3-7 (for patients aged ≥80 years).\n\n  7\\. Willingness of the patient or legally authorized representative to comply with protocol requirements and data collection procedures, with documented informed consent.\n\nExclusion Criteria:\n\n* 1\\. Pre-stroke modified Rankin Scale (mRS) score \\>2. 2. Factors in the target vessel that are expected to prevent completion of endovascular treatment.\n\n  3\\. Concurrent anterior and posterior circulation strokes or multivessel occlusions.\n\n  4\\. Significant mass effect with imaging or clinical signs of obstructive hydrocephalus or tonsillar herniation.\n\n  5\\. Basilar artery occlusion confirmed as chronic by prior imaging or investigator judgment.\n\n  6\\. Presence of untreated intracranial aneurysms, intracranial tumors (except small meningiomas), or intracranial vascular malformations.\n\n  7\\. Intracranial hemorrhage within the past 6 months, including parenchymal brain hemorrhage, intraventricular hemorrhage, or subarachnoid hemorrhage.\n\n  8\\. Presence of active bleeding, coagulation disorders, or uncorrectable bleeding tendencies.\n\n  9\\. Severe heart, liver, or kidney dysfunction or other severe systemic late-stage diseases.\n\n  10\\. Known allergy to iodine contrast agents or other treatment-related drugs. 11. Medically uncontrolled refractory hypertension (defined as persistent systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg) (Note: Participants can be included if their blood pressure is controllable with medication and maintained at an acceptable level).\n\n  12\\. Uncontrollable blood glucose \\\u003C2.8 mmol\u002FL or \\>22.2 mmol\u002FL. 13. Pregnancy or breastfeeding. 14. Life expectancy \\\u003C6 months. 15. Participation in other clinical studies that may affect outcome assessment. 16. Investigator's judgment that the patient is unsuitable for participation in this study or may face significant risks (e.g., due to mental illness, cognitive, or emotional disorders preventing understanding and\u002For compliance with study procedures and\u002For follow-up).",{"count":50,"type":21},348,"INTERVENTIONAL",[53],"NA","A multicenter, prospective, open-label, blinded endpoint, randomized controlled trial designed to evaluate the efficacy and safety of best medical management (BMM) combined with endovascular treatment (EVT) versus BMM alone in acute basilar artery occlusion (BAO) patients with large infarct cores.",[25,56,27,57],"Large Ischemic Core","Endovascular Treatments",[25,59,60],"Endovascular treatment","Large infarct core","RECRUITING","2025-07-21",{"date":64,"type":32},"2025-07-29",{"date":66,"type":21},"2025-08-01",{"date":68,"type":21},"2027-12-31",{"name":70,"class":71},"The First Affiliated Hospital of Hainan Medical University","OTHER_GOV",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":51,"phases":83,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":93,"leadSponsor":95,"locationsCount":40},"100596502","basilar-artery-occlusion-chinese-endovascular-trial-in-patients-with-large-core-infarct-100596502","NCT07046299","Basilar Artery Occlusion Chinese Endovascular Trial in Patients With Large Core Infarct","Safety and Efficacy of Endovascular Therapy for Acute Basilar Artery Occlusion With Large Core Infarct: A Prospective, Multicenter, Randomized, Open-Label Controlled Trial","BAOCHE3","Inclusion Criteria:\n\n1. Posterior circulation acute ischemic stroke within 24 hours from symptom onset\u002Flast seen well.\n2. Occlusion (TIMI 0-1) of the basilar artery or intracranial segments of both vertebral arteries (V4) as evidenced by CTA\u002FMRA\u002FDSA.\n3. Patients with large core infarction in the posterior circulation, defined as a posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) score of 3-5 on CT angiography source images or MR with diffusion-weighted imaging or non-contrast CT.\n4. Age ≥18 and ≤80 years.\n5. Baseline NIHSS score ≥6 at the time of randomization.\n6. No significant pre-stroke functional disability (modified Rankin Scale, mRS ≤ 1).\n7. Informed consent obtained from patient or acceptable patient surrogate.\n\nExclusion Criteria:\n\nClinical exclusion criteria:\n\n1. Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR \\> 3.0.\n2. Baseline platelet count \\\u003C 50000\u002FµL.\n3. Baseline blood glucose of \\\u003C 50mg\u002FdL or \\>400mg\u002FdL.\n4. Severe, sustained hypertension (SBP \\> 220 mm Hg or DBP \\> 110 mm Hg) NOTE: If the blood pressure can be successfully reduced and maintained below these levels using commonly used medications in China for these purposes (including iv antihypertensive drips), the patient can be enrolled.\n5. Patients in whom baseline NIHSS can not be obtained by a neurologist or emergency physician prior to sedation or intubation.\n6. Seizures at stroke onset which would preclude obtaining a baseline NIHSS.\n7. Serious, advanced, or terminal illness with anticipated life expectancy of less than one year.\n8. History of life threatening allergy (more than rash) to contrast medium.\n9. Patients with acute stroke within the first 48 hours after percutaneous cardiac, cerebrovascular interventions and major surgery .\n10. Renal insufficiency with creatinine ≥ 3 mg\u002FdL.\n11. Woman of childbearing potential who is known to be pregnant or lactating or who has a positive pregnancy test on admission.\n12. Subject participating in a study involving an investigational drug or device that would impact this study.\n13. Known diagnosis or clinical suspicion of cerebral vasculitis.\n14. Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations.\n15. Unlikely to be available for 90 days follow-up (e.g. no fixed home address, visitor from overseas).\n\n    Neuroimaging exclusion criteria:\n16. Pons-midbrain-index of ≥ 4 on CT angiography source images or MR with diffusion-weighted imaging or non-contrast CT.\n17. CT or MR evidence of hemorrhage (the presence of microbleeds on MRI is allowed).\n18. Complete cerebellar infarct on CT or MRI with significant mass effect and compression of the fourth ventricle.\n19. Complete bilateral thalamic infarction on CT or MRI.\n20. Evidence of vertebral occlusion, high grade stenosis or arterial dissection in the extracranial or intracranial segment that cannot be treated or will prevent access to the intracranial clot or excessive tortuosity of cervical vessels precluding device delivery\u002Fdeployment.\n21. Subjects with occlusions in both anterior and posterior circulation.\n22. Evidence of intracranial tumor (except small meningioma).","80 Years",{"count":82,"type":21},314,[53],"This study evaluates the safety and efficacy of endovascular therapy for acute basilar artery occlusion with large core infarcts in a multicenter randomized trial.",[25,26,27],[87,27,88],"Endovascular Therapy","Randomized Controlled Trial","2025-06-29",{"date":91,"type":32},"2025-07-01",{"date":91,"type":21},{"date":94,"type":21},"2028-11-30",{"name":96,"class":39},"Capital Medical University"]